For years, the STI headlines have mostly gone one way: up. This week brought a rare piece of good news. A study published on October 21, 2026 in Nature Health found that after Australia issued national guidance on doxyPEP, an antibiotic dose taken after sex, syphilis and chlamydia diagnoses among gay and bisexual men fell well below where earlier trends were heading.

The short version: In the 27 months after the guidance, syphilis diagnoses were 55% lower and chlamydia diagnoses 36% lower than researchers projected from earlier trends. Gonorrhea didn't budge. DoxyPEP doesn't protect against HIV, herpes or HPV, and it's currently recommended only for specific groups. But this is the first national-level evidence that it can bend the curve for a whole population, not just for people in a trial.

What is doxyPEP?

DoxyPEP (also written "doxy PEP") stands for doxycycline post-exposure prophylaxis. According to CDC's doxy PEP guidance, it means taking a single 200 mg dose of the antibiotic doxycycline as soon as possible, within 72 hours after oral, vaginal or anal sex, and no more than 200 mg in any 24 hours. It's prescribed by a provider, not bought over the counter.

Think of it as a "morning-after" step for certain bacterial STIs. It isn't a daily pill, and it isn't a substitute for testing.

What the new study found

The research was led by the Burnet Institute in Melbourne and drew on Australia's ACCESS sentinel surveillance network, a collaboration between the Burnet Institute, the Kirby Institute and the National Reference Laboratory. According to the Nature Health paper:

• The scale was large. Researchers analyzed records for 78,560 gay and bisexual men tested at 29 sexual health and general practice clinics between January 2022 and December 2025.
• Syphilis dropped sharply. After national doxyPEP guidance was released in September 2023, the model estimated about 2,430 syphilis diagnoses over the following 27 months, versus about 5,403 if earlier trends had continued. That's 55% lower than expected.
• Chlamydia fell too. Diagnoses were 36% lower than expected.
• Gonorrhea did not. There was no significant change, which the authors say fits trial evidence that doxyPEP works less consistently against gonorrhea, likely because of tetracycline resistance. They note resistance has reached up to 60% of gonorrhea samples in some Australian jurisdictions.
• The biggest drop was where guidance pointed. Among men who'd had an STI in the previous 12 months, syphilis was 64% lower than expected. Similar reductions showed up among men using HIV PrEP, and in a combined group of men who were using PrEP or living with HIV.
• Prescribing shifted. In the 16 clinics with usable prescription data, about half of all doxycycline prescriptions carried doxyPEP-style instructions by December 2025.

"We already know from clinical trials that doxyPEP could substantially reduce an individual's risk of syphilis and chlamydia. What we haven't known until now is whether those benefits could translate into meaningful changes across a wider population," lead author Dr. Michael Traeger said in the Burnet Institute's announcement.

What the study can't tell us

This was an observational study. It shows that STI declines lined up with doxyPEP guidance and rising prescriptions, but it can't prove doxyPEP alone caused them. The clinics in the network may over-represent people who are very engaged with sexual health care. The data also couldn't separate results for transgender participants. The authors are clear that ongoing monitoring of antibiotic resistance matters as use grows.

Who doxyPEP is recommended for right now

Guidance is narrow on purpose, partly to limit antibiotic resistance:

• In the U.S., CDC recommends that providers discuss doxyPEP with gay, bisexual and other men who have sex with men, and transgender women, who've had at least one bacterial STI (syphilis, chlamydia or gonorrhea) in the past 12 months. CDC says there isn't yet enough evidence to recommend it for other groups, including cisgender women.
• Globally, the World Health Organization issued its first doxyPEP recommendation on May 28, 2026, also for men who have sex with men and transgender women. WHO says use should prioritize people with recent or recurrent STIs, especially syphilis, and come with antibiotic-resistance monitoring.

CDC also advises STI and HIV testing every 3 to 6 months for people using doxyPEP, and lists side-effect tips: take it with water and food, stay upright for an hour, avoid dairy, antacids and iron or calcium supplements within two hours, and use sunscreen. CDC notes that questions remain about long-term resistance and effects on the microbiome.

What this means for dating and relationships

It's one more layer, not a force field

Doxycycline is an antibiotic, so it works on bacteria. It does nothing against viral infections such as HIV, herpes (HSV) or HPV. If you're living with herpes or HIV, or dating someone who is, your existing tools still do the heavy lifting: HIV treatment and U=U, PrEP, suppressive herpes therapy, condoms and vaccines. Our guide to layering condoms, antivirals and PrEP walks through how those fit together. If you're HIV-positive and undetectable, here's a refresher on what U=U means for dating.

It can make the testing talk easier

Bringing up STI testing with a new partner can feel loaded. News like this gives you an easy, non-judgmental way in: "Have you heard about doxyPEP? Is it something your provider has talked about?" That opens a conversation about when you each last tested and what protection you use. For pacing, see how often to get tested for STDs. If you're ready to share your own status, the disclosure talk has practical scripts.

A positive result is not a character judgment

Syphilis and chlamydia are curable with treatment. The study's authors even point to possible broader benefits of doxyPEP, including less anxiety and stigma around recurring STIs. If a test comes back positive, it's a health task, not a verdict on you. Our explainer on which STDs are curable and which are permanent can help put a result in perspective.

Gonorrhea still needs attention

With no drop in gonorrhea and resistance a growing concern, regular testing and condoms remain important. We covered the bigger picture in super gonorrhea is running out of treatment options.

Quick FAQ

Does doxyPEP protect against HIV or herpes?

No. It's an antibiotic that targets certain bacterial STIs. It doesn't work against viruses like HIV, HSV or HPV.

Can I just take leftover doxycycline after sex?

Talk to a provider first. CDC guidance is built around a prescription, the right dose, regular STI and HIV testing, and a check on your other medications.

Is doxyPEP recommended for women?

Not yet. CDC says the evidence is currently insufficient for other populations, including cisgender women, and more studies are needed.

Why didn't gonorrhea go down?

The authors say it's consistent with trial data showing weaker, less consistent protection against gonorrhea, likely because many gonorrhea strains resist tetracycline-class antibiotics.

The bottom line

Prevention science for STIs is moving, and it's moving in a direction that can make sex and dating feel a little less fraught. Being honest with partners, testing regularly and using the tools that fit your life are still the foundation. And if you want to meet people who already understand all of this, MeetPositives has welcoming communities for HIV dating, herpes dating and STD dating.

This article is for general information only and isn't medical advice. Talk with a qualified healthcare provider about STI prevention, testing and whether doxyPEP is right for you.